Cardio-Oncology

CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis What is VTE: Why Does it Matter? Challenges of Clinical Trials in Cardio-Oncology: Navigating Surrogate Outcomes and Identifying Patients at Risk of Late Cardiovascular Complications Response by Glargaard and Thune to Letters Regarding Article, “A Randomized Trial of Thoracentesis in Acute Heart Failure” Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis Minimally Invasive Diagnosis of a Cardiac Mass: Resolving Clinical-Imaging Discordance Response by Abdel-Qadir et al to Letter Regarding Article, “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study” Immune Checkpoint Inhibitor Therapy and Acute Coronary Syndrome: A Review of Mechanisms and Management Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy